Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Roivant Sciences Ltd (NQ: ROIV ) 11.57 -0.20 (-1.70%) Streaming Delayed Price Updated: 4:00 PM EDT, Sep 26, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Roivant Sciences Ltd < Previous 1 2 3 4 5 6 7 Next > Merck Nabs Prometheus Bio For $10.8 Billion As Keytruda Patent Expirations Loom April 17, 2023 Merck is branching into immune-mediated diseases with this takeover. Via Investor's Business Daily Prometheus Biosciences, XPeng And Other Big Stocks Moving Higher In Monday's Pre-Market Session April 17, 2023 U.S. stock futures traded mixed this morning. Here are some big stocks recording gains in today’s pre-market trading session. Prometheus Biosciences, Inc. (NASDAQ: RXDX) shares jumped 70.1% to $193.93... Via Benzinga Lokavant Hires Experienced Leaders to Accelerate Growth Trajectory April 04, 2023 From Lokavant Via Business Wire Analyst Expectations for Roivant Sciences's Future March 16, 2023 Via Benzinga Roivant Sciences Highlights Topline Data From Atopic Dermatitis Drug In Patients As Young As 2 Years March 15, 2023 Via Benzinga Expert Ratings for Roivant Sciences February 13, 2023 Via Benzinga Roivant Sciences's Earnings Outlook February 10, 2023 Via Benzinga Lokavant Emerges from Roivant Sciences with Multiple Industry Partnerships to Accelerate Impact on Clinical Research April 04, 2023 From Lokavant Via Business Wire 7 Biotech Stocks to Buy for Breakthrough Treatments and Cures March 29, 2023 For those that can handle the heat, these biotech stocks to buy undergird some of the most powerful innovations in medicine. Via InvestorPlace Covant and Boehringer Ingelheim Collaborate to Develop a Novel ADAR1 Inhibitor for Use in Cancer Patients March 28, 2023 From Covant Therapeutics Via GlobeNewswire Where Roivant Sciences Stands With Analysts January 19, 2023 Via Benzinga Why Citi Trends Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session March 21, 2023 Gainers U.S. Xpress Enterprises, Inc. (NYSE: USX) shares surged 298% to $5.97 after Knight-Swift Transportation agreed to acquire the company for $6.15 per share. Via Benzinga Why Shares of Roivant Sciences Were Down Tuesday March 21, 2023 After a run-up last week prompted by positive clinical trial results, the stock has given back its recent gains. Via The Motley Fool The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector March 15, 2023 To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy. Via InvestorPlace Roivant Reports Positive Topline Results from ADORING 2 Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% Once Daily in Adults and Children as Young as 2 Years Old March 15, 2023 From Roivant Sciences Via GlobeNewswire Roivant to Host Investor Call at 8:00 AM ET on Wednesday, March 15 to Review Results from ADORING 2 Phase 3 Trial in Atopic Dermatitis March 14, 2023 From Roivant Sciences Via GlobeNewswire Proteovant Therapeutics to Present Preclinical Data from Estrogen Receptor and IKZF2 Protein Degrader Programs March 14, 2023 PVTX-321 and PVTX-405 Achieve Development Candidate Nomination From Roivant Sciences Via GlobeNewswire Covant Therapeutics Announces the Formation of its Scientific Advisory Board to Support Platform and Pipeline Advancement March 07, 2023 From Roivant Sciences Via GlobeNewswire Roivant Sciences Announces Change to its Board of Directors February 21, 2023 From Roivant Sciences Via GlobeNewswire Immunovant Could Potentially Be An M&A Target, Writes Analyst February 15, 2023 Via Benzinga Mixed Signals On Valentine's Day: How Stocks Are Reacting To January Inflation Data February 14, 2023 Inflation cooled slightly in January, but saw increases in some areas due to the impact of surging food, energy and shelter prices on consumers, the U.S Labor Department said Tuesday. Via Benzinga Earnings Scheduled For February 13, 2023 February 13, 2023 Companies Reporting Before The Bell • EuroDry (NASDAQ:EDRY) is expected to report quarterly earnings at $2.68 per share on revenue of $21.20 million. Via Benzinga Roivant Sciences Reports Financial Results for the Third Quarter Ended December 31, 2022 and Provides Business Update February 13, 2023 From Roivant Sciences Via GlobeNewswire Roivant Sciences Announces Pricing of Upsized Public Offering of Common Shares February 02, 2023 From Roivant Sciences Via GlobeNewswire Roivant Sciences Announces Proposed Public Offering of Common Shares February 01, 2023 From Roivant Sciences Via GlobeNewswire Roivant to Report Financial Results for the Third Quarter Ended December 31, 2022 on Monday, February 13, 2023 January 30, 2023 From Roivant Sciences Via GlobeNewswire Roivant Touts Encouraging Early Data From Ulcerative Colitis Candidate January 04, 2023 Via Benzinga Roivant Announces Statistically Significant and Clinically Meaningful Results from the Induction Period of TUSCANY-2, a Large Global Phase 2b Study of Subcutaneous RVT-3101 for the Treatment of Ulcerative Colitis in Both the Overall and the Biomarker January 04, 2023 From Roivant Sciences Via GlobeNewswire Moderna To Rally Over 42%? Here Are 10 Other Price Target Changes For Monday December 19, 2022 Morgan Stanley cut VTEX (NYSE: VTEX) price target from $7 to $5. Morgan Stanley analyst Cesar Medina downgraded the stock from Overweight to Equal-Weight. VTEX shares fell 4.9% to close at $3.52 on... Via Benzinga Why Roivant Sciences' Shares Are Up Thursday December 01, 2022 The company is collaborating with Pfizer to create a portfolio company to develop an encouraging drug to treat ulcerative colitis. Via The Motley Fool < Previous 1 2 3 4 5 6 7 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.